Nuwellis, Inc. (NUWE) stock
NUWENasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/3082% below fair value
$4.90−0.13 (-2.58%)
Close on Nov 13, 2026Market cap $2.65MP/E –Yield –
Nuwellis EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$888.65. The highest annual figure on record is -$888.65 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$888.65 | – |
| FY2024 | Dec 31, 2024 | -$12365.50 | – |
| FY2023 | Dec 31, 2023 | -$529288.20 | – |
| FY2022 | Dec 31, 2022 | -$4298647.50 | – |
| FY2021 | Dec 31, 2021 | -$14681772.00 | – |
| FY2020 | Dec 31, 2020 | -$54348178.50 | – |
| FY2019 | Dec 31, 2019 | -$1420591095.00 | – |
| FY2018 | Dec 31, 2018 | -$6439265910.00 | – |
| FY2017 | Dec 31, 2017 | -$80224940565.00 | – |
| FY2016 | Dec 31, 2016 | -$1146916690920.00 | – |
| FY2015 | Dec 31, 2015 | -$1883003938200.00 | – |
| FY2014 | Dec 31, 2014 | -$1938197646000.00 | – |
| FY2013 | Dec 31, 2013 | -$2194912566000.00 | – |
| FY2012 | Dec 31, 2012 | -$2541477708000.00 | – |
| FY2011 | Dec 31, 2011 | -$3825052308000.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$5.81 | – |
| Q2 FY2026 | Jun 30, 2026 | -$26.64 | – |
| Q1 FY2026 | Mar 31, 2026 | -$76.65 | -103.0% |
| Q3 FY2025 | Sep 30, 2025 | $177.16 | – |
| Q2 FY2025 | Jun 30, 2025 | -$2134.19 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1012.55 | – |
| Q3 FY2024 | Sep 30, 2024 | $2563.05 | – |
| Q2 FY2024 | Jun 30, 2024 | -$27713.70 | – |
| Q1 FY2024 | Mar 31, 2024 | -$35441.70 | – |
| Q3 FY2023 | Sep 30, 2023 | -$93006.90 | – |
| Q2 FY2023 | Jun 30, 2023 | -$187645.50 | – |
| Q1 FY2023 | Mar 31, 2023 | -$296352.00 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1889244.00 | – |
| Q2 FY2022 | Jun 30, 2022 | -$2092471.50 | – |
| Q1 FY2022 | Mar 31, 2022 | -$2184052.50 | – |
| Q3 FY2021 | Sep 30, 2021 | -$3820162.50 | – |
| Q2 FY2021 | Jun 30, 2021 | -$3667356.00 | – |
| Q1 FY2021 | Mar 31, 2021 | -$8251551.00 | – |
| Q3 FY2020 | Sep 30, 2020 | -$10594584.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$15790005.00 | – |
| Q1 FY2020 | Mar 31, 2020 | -$58779567.00 | – |
| Q3 FY2019 | Sep 30, 2019 | -$260382276.00 | – |
| Q2 FY2019 | Jun 30, 2019 | -$294916545.00 | – |
| Q1 FY2019 | Mar 31, 2019 | -$1752690555.00 | – |
| Q3 FY2018 | Sep 30, 2018 | -$1298855250.00 | – |
| Q2 FY2018 | Jun 30, 2018 | -$1991068695.00 | – |
| Q1 FY2018 | Mar 31, 2018 | -$2310434280.00 | – |
| Q3 FY2017 | Sep 30, 2017 | -$9733774050.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$20066549580.00 | – |
| Q1 FY2017 | Mar 31, 2017 | -$74982149550.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?